LEAP2 has been reported to be a promising therapeutic target for obesity and other metabolic diseases, with the view that further increasing the LEAP2–ghrelin molar ratio may help restrict food intake [14,84]. Here, LEAP2 is linked to obesity due to melanocortin 4 receptor deficiency.